The Medical Device Software Development Life Cycle: A Guide to Compliant Software Development

Software has become integral to modern medical technology. It may control the operation of a physical device, analyze patient data, enable connectivity between systems, support clinical decision-making, or function independently as Software as a Medical Device (SaMD). As these technologies become more sophisticated, their development requires a disciplined lifecycle that accounts for patient safety, product performance, cybersecurity, risk management, quality, and regulatory expectations from the outset.

The medical device software development life cycle (SDLC) provides that structure. An effective SDLC connects product requirements and engineering decisions with the evidence necessary to demonstrate that software performs as intended and that associated risks have been appropriately addressed.

For manufacturers, the objective should not be to develop a product first and construct a compliance narrative afterward. Regulatory readiness is strongest when it develops alongside the software itself.

What Is the Medical Device Software Development Life Cycle?

The medical device software development life cycle is a structured framework for planning, designing, developing, testing, releasing, maintaining, and eventually retiring medical device software.

Unlike a conventional software development process, the medical device SDLC must account for the regulatory environment surrounding the product. Requirements, design decisions, risk controls, tests, anomalies, configuration changes, and other development activities can become part of the evidence used to support regulatory review.

The lifecycle can apply to several forms of software, including software embedded within a physical medical device, software that controls or supports a device, and software that itself performs a medical purpose as SaMD.

The appropriate development process will vary based on the technology, intended use, architecture, and risks associated with the product. However, the underlying principle remains consistent: development activities should produce traceable evidence demonstrating how the organization translated its intended use and requirements into a safe and effective, controlled product.

What Regulations and Standards Apply to Medical Device Software?

Medical device software developers operate within an interconnected regulatory framework. The exact requirements depend on the product, its intended market, and the nature of its software functions.

IEC 62304 is a foundational standard for medical device software lifecycle processes and establishes a framework for software development and maintenance. FDA recognizes IEC 62304 Edition 1.1, which applies when software is itself a medical device or is embedded or integral to a medical device.

Risk management is closely connected to the software lifecycle. ISO 14971 provides the framework for applying risk management to medical devices and is also an FDA-recognized consensus standard. Depending on the product, additional standards and guidance related to usability engineering, cybersecurity, human factors, or other areas may apply.

The U.S. quality framework has also changed. FDA's Quality Management System Regulation (QMSR) became effective February 2, 2026, incorporating ISO 13485:2016 by reference into 21 CFR Part 820.

For software specifically, FDA's Content of Premarket Submissions for Device Software Functions guidance describes recommended documentation supporting FDA's evaluation of the safety and effectiveness of device software functions. Identifying applicable requirements early is important. Attempting to reconstruct months or years of development evidence immediately before a submission can expose gaps that require significant remediation.

What Are the Stages of the Medical Device Software Development Life Cycle?

Although organizations may structure their development processes differently, several fundamental activities typically extend across the medical device software lifecycle.

1. Planning and Defining the Software

Effective software development begins by establishing what is being developed, why it is being developed, and the regulatory context in which it will operate.

Teams should define the software's intended use, users, operating environment, system boundaries, interfaces, and role within the overall medical device. Regulatory strategy should inform this work early because device classification, intended claims, applicable standards, and submission pathway can influence the evidence required later.

A software development plan can establish responsibilities, lifecycle activities, development methods, configuration management practices, documentation requirements, and review processes.

This is also an opportunity to align engineering, quality, regulatory, and cybersecurity stakeholders. Early alignment reduces the risk that engineering decisions will later conflict with regulatory or documentation requirements.

2. Defining Software Requirements

Requirements create the foundation against which the software will eventually be evaluated.

High-quality software requirements should be clear, specific, testable, and traceable. Depending on the product, they may address functionality, performance, interfaces, data handling, safety, cybersecurity, alarms, error handling, and other characteristics.

Traceability is particularly important. Teams should be able to demonstrate logical relationships among user needs, system and software requirements, identified risks, risk controls, design outputs, and verification activities.

This structure allows an organization to demonstrate why a feature exists, what requirements it must satisfy, what risks are associated with it, and what objective evidence confirms appropriate implementation.

3. Software Architecture and Detailed Design

Once requirements have been established, teams translate them into an architecture and detailed software design.

Architecture documentation may describe software components, interfaces, dependencies, data flows, external systems, databases, communications pathways, and third-party components. Detailed design then defines how individual software elements implement their respective requirements.

Architecture also has direct implications for safety and cybersecurity. The way information moves through a connected medical device, for example, can determine its attack surface, security boundaries, and potential failure modes.

For complex products, clear architecture documentation can therefore become an important bridge between engineering implementation, risk management, cybersecurity analysis, and regulatory evidence.

4. Risk Management and Cybersecurity

Risk management should not be treated as a discrete exercise completed at one point in development. It should remain active throughout the lifecycle.

Software teams need to identify reasonably foreseeable hazards, analyze associated risks, establish appropriate controls, and verify that those controls perform as intended. As the design evolves, new information may require the risk analysis to evolve with it.

For connected medical devices, cybersecurity adds another dimension to this process.

FDA's February 2026 cybersecurity guidance addresses cybersecurity throughout device design and the documentation recommended for premarket submissions involving devices with cybersecurity risk. The guidance also addresses requirements associated with cyber devices under Section 524B of the Federal Food, Drug, and Cosmetic Act.

Relevant activities can include threat modeling, security requirements, vulnerability assessments, penetration testing, management of third-party software, Software Bills of Materials (SBOMs), secure update mechanisms, and postmarket vulnerability planning.

Third-party components deserve particular attention. FDA recommends that proprietary and third-party software be assessed for cybersecurity risk and that software components and associated risks be documented.

Cybersecurity should therefore develop alongside the product rather than becoming a pre-submission documentation exercise.

5. Software Implementation

During implementation, developers convert approved requirements and designs into functioning software.

Disciplined development practices are critical during this phase. These may include coding standards, source control, peer review, build management, issue tracking, and configuration management.

Organizations should maintain sufficient control over software versions and changes to establish precisely what was developed and tested. Third-party and open-source components also need appropriate oversight because changes in external components can introduce new functional or security risks.

The goal is not documentation for its own sake. It is to maintain a defensible connection between the approved design, the implemented software, and the version ultimately evaluated for release.

6. Software Verification and Validation

Verification and validation provide objective evidence that the software has been developed correctly and is appropriate for its intended use.

Verification asks whether specified requirements have been correctly implemented. Validation evaluates the finished product in relation to user needs and intended uses.

Depending on the device, testing may include unit, integration, system, regression, performance, cybersecurity, and other forms of testing. Validation activities may also involve usability or simulated-use evaluations where applicable.

Tests should include predefined acceptance criteria, documented results, and clear traceability to the requirements or controls they evaluate. When failures or anomalies occur, teams should document their disposition and assess their potential impact.

Strong testing evidence should allow an independent reviewer to follow a coherent chain from requirement to implementation to objective evidence.

7. Release and Regulatory Submission

Before release, the organization should establish that the appropriate lifecycle activities have been completed and that the software configuration intended for release is clearly identified.

Outstanding anomalies should be documented and evaluated. Required verification and validation activities should be complete, configuration records should reflect the final product, and relevant risk documentation should be current.

For products requiring premarket review, the development record then becomes an important source of regulatory evidence.

FDA's current device software guidance uses a risk-based approach with Basic and Enhanced Documentation Levels to identify the recommended information supporting premarket review.

Submission preparation should not simply involve collecting documents into a package. The evidence should tell a consistent story about what the software does, how it was developed, what risks were identified, how those risks were controlled, and why the available evidence supports safety and effectiveness.

8. Postmarket Maintenance and Software Changes

Software development does not end when a device reaches the market.

Bug fixes, cybersecurity patches, operating system changes, third-party component updates, performance improvements, and new features can all require lifecycle activities after release.

Organizations need processes for evaluating proposed changes and determining their effects on requirements, architecture, risk, cybersecurity, verification, validation, and regulatory status. Complaints, field experience, cybersecurity intelligence, and other postmarket information may also identify issues that require corrective action.

For connected products, continuous vulnerability monitoring is particularly important. Manufacturers need to understand not only the software they created but also the external components on which their products depend.

A mature SDLC therefore operates as a continuous system rather than a linear project that concludes at launch.

Where Do AI and Machine Learning Fit into the Medical Device Software Lifecycle?

AI/ML-enabled medical devices introduce additional considerations because product performance may depend not only on traditional source code but also on data, model architecture, training methods, and model behavior.

Development evidence may need to address dataset provenance and suitability, training and test data separation, model performance, robustness, potential bias, subgroup performance, failure modes, and model versioning.

Traceability remains essential. Organizations need to connect intended use and product claims to model requirements, risk controls, performance evaluations, and supporting evidence.

Lifecycle planning also becomes particularly important when manufacturers anticipate modifying AI-enabled device software after authorization. The regulatory framework for AI-enabled device software functions continues to evolve, making it important to consider both current product evidence and the mechanisms by which future changes will be evaluated and controlled.

For technical teams, one of the central challenges is often not a lack of engineering evidence but translating highly specialized development artifacts into a regulatory narrative that allows reviewers to understand what the model does, how it was evaluated, and how its risks are controlled.

What Are Common Medical Device Software Development Life Cycle Mistakes?

Many software compliance problems originate less from a lack of technical capability than from a disconnect among engineering, quality, risk, cybersecurity, and regulatory activities.

Common issues include:

• Vague or untestable requirements
• Incomplete traceability
• Risk analyses that do not remain synchronized with design changes
• Insufficient configuration control
• Incomplete third-party software documentation
• Testing that cannot be clearly mapped back to requirements

Another recurring problem is timing. If cybersecurity, regulatory documentation, or submission strategy enters the development process too late, teams may discover that the necessary evidence was never generated or that existing documentation does not adequately support the final product.

These gaps can require teams to reconstruct design rationale, repeat testing, revise risk documentation, or respond to avoidable regulatory questions. The more sophisticated the software becomes, the more valuable continuous regulatory alignment becomes.

How Can Medical Device Teams Make the SDLC More Efficient?

Regulatory rigor does not require unnecessary process.

An efficient SDLC integrates regulatory and quality considerations into existing development activities wherever practical. Rather than generating documentation independently from engineering work, organizations can structure normal development outputs so they also contribute to the evidence needed for design control and regulatory review.

Maintaining traceability continuously is generally more efficient than recreating it before submission. Periodic evidence reviews can similarly identify missing requirements, incomplete risk controls, or testing gaps while they remain relatively straightforward to address.

The development process should also be proportional to the product. Processes, documentation, and controls should reflect the intended use, architecture, complexity, and risk of the software.

Ultimately, an effective medical device SDLC should provide control without creating unnecessary friction. Engineering, regulatory, quality, and cybersecurity activities should reinforce one another rather than operate as parallel workstreams.

How Can Quality Commercial Consultants Support Medical Device Software Teams?

For organizations developing SaMD, connected devices, AI/ML-enabled products, and other software-enabled medical technologies, translating technical development into defensible regulatory evidence can require specialized expertise.

Quality Commercial Consultants (QCC) works with medical device and health technology organizations to identify compliance gaps, develop submission-ready documentation, and align existing technical evidence with regulatory expectations. QCC's services include regulatory compliance and QMS planning, FDA 510(k) support, cybersecurity compliance, cybersecurity testing support, and AI/ML compliance documentation.

For teams approaching a 510(k), QCC can support evidence mapping, gap identification, submission organization, consistency reviews, specialized cybersecurity and AI/ML content, and responses to FDA Additional Information requests.

QCC's approach is designed to meet development teams where they are. Rather than imposing a separate compliance infrastructure by default, QCC works with existing artifacts and development environments to translate complex technical work into clear, traceable, reviewer-ready evidence.

Build Regulatory Readiness into the Software Lifecycle

A well-designed medical device software development life cycle is the framework through which engineering decisions, patient safety, risk management, cybersecurity, quality, and regulatory evidence remain connected throughout the life of the product.

Organizations that build regulatory readiness into development are better positioned to identify gaps early, maintain meaningful traceability, respond to change, and prepare coherent submissions without unnecessary late-stage remediation.

As software-enabled medical devices continue to evolve, that integration becomes increasingly important. SaMD, connected devices, and AI/ML-enabled technologies require development processes capable of supporting innovation while maintaining disciplined control over risk and evidence.

Quality Commercial Consultants helps medical device and health technology teams navigate that intersection. If your organization is establishing its regulatory strategy, preparing a 510(k), addressing cybersecurity requirements, documenting an AI/ML-enabled device, or responding to regulatory questions, QCC can help translate your technical work into clear, defensible evidence that supports the path to market.